Tabcorp’s Lotteries business donates $600,000 to Zero Childhood Cancer Program
29 April 2020
A world-leading personalised medicine program being developed in Australia to save children battling aggressive cancer has received a $600,000 donation from Tabcorp’s lotteries business.
The support from Golden Casket, part of the Lott, Australia’s official lotteries, includes Golden Casket unclaimed prize money.
The Zero Childhood Cancer Program is Australia’s first personalised medicine treatment program and is focused on children diagnosed with cancer who have been given a less than a 30% chance of survival.
Led by the Children’s Cancer Institute and the Kids Cancer Centre at Sydney Children’s Hospital, Randwick, The Zero Childhood Cancer Program brings together all major Australian clinical and research centres working in childhood cancer.
Since the national clinical trial launched in September 2017, over 300 children and young people with aggressive cancer have been enrolled. For 74% of these patients, the program has successfully identified a personalised treatment plan aimed to target the specific genetic changes driving their cancer, in just nine weeks.
The Lott’s $600,000 contribution will be used to fund the national clinical trial which will see 400 children join by the end of the year.
The Lott Managing Director Sue van der Merwe said Australia’s official lotteries was honoured to be part of this truly revolutionary journey towards curing childhood cancer.
“This partnership continues a long-held tradition for Australian lotteries of funding vital medical initiatives,” she said.
“We’re committed to giving back to the communities in which we operate and achieving better outcomes for childhood cancer is something we are particularly passionate about.
“This program is giving new hope to families and children going through an unimaginable ordeal.
“We want more children with cancer to have the opportunity to access personalised cancer treatment plans and with today’s $600,000 donation, along with the incredible work from the research and medical partners, that will be possible.”